Addex Pharmaceuticals SA : Addex Pharmaceuticals 2011 Financial Results This Thursday
02/21/2012| 01:06pm US/Eastern
Recommend:
Geneva, Switzerland, 21 February 2012 - Addex Pharmaceuticals
(SIX:ADXN), a leading biopharmaceutical company pioneering
allosteric modulation-based drug discovery and development
will discuss its full-year 2011 financial results, provide a
business update and review its pipeline during a
teleconference and webcast for investors, analysts and the
media this Thursday.
Title:
Addex Full-Year 2011 Financial Results Conference Call
Date:
February 23, 2012
Time:
16:00 CET (15:00 GMT/10:00 EST)
To participate, please listen to the webcast or call one of
the following telephone numbers. RSVP is not necessary.
Dial-in numbers: +41 91 610 56 00 (Europe)
+44 203 059 58 62 (UK)
+1 866
291 4166
(USA)
The live webcast, slides, webcast replay and transcript, will
be available at www.addexpharma.com.
Addex Pharmaceuticals (www.addexpharma.com)
discovers and develops an emerging class of small molecule
drugs, called allosteric modulators, which have the potential
to be more specific and confer significant therapeutic
advantages over conventional "orthosteric" small molecule or
biological drugs. The Company uses its proprietary discovery
platform to address receptors and other proteins that are
recognized as attractive targets for modulation of important
diseases with unmet medical needs. The Company's two lead
products are being investigated in Phase IIa clinical
testing: dipraglurant (ADX48621, an mGluR5 negative
allosteric modulator or NAM) is being developed by Addex to
treat Parkinson's disease levodopa-induced dyskinesia
(PD-LID); and ADX71149 (mGluR2 positive allosteric modulator
or PAM) is being developed by our partner Janssen
Pharmaceuticals Inc. to treat schizophrenia. Addex also is
advancing several preclinical programs including: GABABR PAM
for pain, overactive bladder and other disorders; mGluR4 PAM
for Parkinson's, anxiety and other diseases; GLP1R PAM
for type 2 diabetes; mGluR2 NAM for treating Alzheimer's
disease and depression; and FSHR/LHR NAM for sex hormone
dependent tumors & reproductive system disorders. In
addition, Addex has discovery programs to identify allosteric
modulators of: receptor tyrosine kinase (RTK) superfamily,
including TrkB PAM for treating neurodegenerative diseases
(e.g. Alzheimer's, Parkinson's and Huntington's diseases);
and TNF receptor superfamily, including TNFR1 NAM for
inflammation (e.g. rheumatoid arthritis) and other diseases.
Chris Maggos
Business Development & Communication
Addex Pharmaceuticals
+41 22 884 15 11
chris.maggos(at)addexpharma.com
Disclaimer: The foregoing release may contain forward-looking
statements that can be identified by terminology such as
"not approvable", "continue",
"believes", "believe", "will",
"remained open to exploring", "would",
"could", or similar expressions, or by express or
implied discussions regarding Addex Pharmaceuticals Ltd, its
business, the potential approval of its products by
regulatory authorities, or regarding potential future
revenues from such products. Such forward-looking statements
reflect the current views of Addex Pharmaceuticals Ltd
regarding future events, future economic performance or
prospects, and, by their very nature, involve inherent risks
and uncertainties, both general and specific, whether known
or unknown, and/or any other factor that may materially
differ from the plans, objectives, expectations, estimates
and intentions expressed or implied in such forward-looking
statements. Such may in particular cause actual results with
allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 or
other therapeutic targets to be materially different from any
future results, performance or achievements expressed or
implied by such statements. There can be no guarantee that
allosteric modulators of mGluR2, mGluR4, mGluR5, mGluR7 will
be approved for sale in any market or by any regulatory
authority. Nor can there be any guarantee that allosteric
modulators of mGluR2, mGluR4, mGluR5, mGluR7 or other
therapeutic targets will achieve any particular levels of
revenue (if any) in the future. In particular,
management's expectations regarding allosteric
modulators of mGluR2, mGluR4, mGluR5, mGluR7 or other
therapeutic targets could be affected by, among other things,
unexpected actions by our partners, unexpected regulatory
actions or delays or government regulation generally;
unexpected clinical trial results, including unexpected new
clinical data and unexpected additional analysis of existing
clinical data; competition in general; government, industry
and general public pricing pressures; the company's
ability to obtain or maintain patent or other proprietary
intellectual property protection. Should one or more of these
risks or uncertainties materialize, or should underlying
assumptions prove incorrect, actual results may vary
materially from those anticipated, believed, estimated or
expected. Addex Pharmaceuticals Ltd is providing the
information in this press release as of this date and does
not undertake any obligation to update any forward-looking
statements contained in this press release as a result of new
information, future events or otherwise, except as may be
required by applicable laws.
Recommend :
